Menu

Dr. Roman Perez-Soler is considered an international cancer expert in experimental cancer therapy, and a recipient of numerous awards for his accomplishments, particularly for his contributions to lung cancer research.

Dr. Perez-Soler has published over a hundred articles, and papers including, “Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib,” published in the Cancer Chemother Pharmacol in January of 2009. He also co-authored, “Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK,” and “Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene,” published in Molecular Pharmacology and the Journal of Thoracic Oncology respectively.

Main Speciality: Oncology

Other Interests & Specialties: Hematologic oncology, lung cancer and experimental cancer therapy.

Certifications, Awards & Accolades: American Board of Internal Medicine Certifications in Internal Medicine and Medical Oncology, Super Doc Award, Top Doctors: New York Metro Area Award, Distinguished Alumnus Award, New York Magazine: Top Doctors Award, Faculty Excellence Award

Education & Experience:

Publications:
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesotheliomaJournal of Clinical Oncology. May 2005;23(15):3495-3501. doi: 10.1200/JCO.2005.00.802

Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidenceExpert Opinion on Pharmacotherapy. January 2019;20(1):95-102. doi: 10.1080/14656566.2018.1546290

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung CancersClinical Cancer Research. April 2018;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924

Photo of Dr. Roman Perez-Soler

Get Help Contacting Dr. Roman Perez-Soler


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe